Author

Roland Tillmann Ullrich

University of Cologne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2

Frequent Co-Authors

Albrecht StenzingeriD· 1 shared Alexander F. vom SteiniD· 1 shared Amin Mokhlesi· 1 shared Amirhossein SakhtemaniD· 1 shared An HendrixiD· 1 shared Andreas SchneeweißiD· 1 shared Andreas Unterberg· 1 shared Anne Zirkel· 1 shared

Activity by Year

2017-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Albrecht StenzingerORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Prospective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncology

Annika Schneider, Julia Wortmann, Cecilia Bang Jensen, Leonardo Estrada Duenas, Maria‐Veronica Teleanu, Amirhossein Sakhteman, Firas Hamood, Florian P Bayer, Christoph Stange, Jeremiah Bintang Santoso, Jennifer Hüellein, Nindo B. Punturi, Lee Dolat, Peter Horak, Resch Moritz, , Bernhard Küster

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

bioRxiv · Jul 9, 2026 · PreprintCancer Biology

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells:Potency despite risk of translocations

Jan-Malte Kleid, Michael Damrat, Milita Darguzyte, Manuel Rhiel, Natascha E. Stumpf, Tabea Kleitke, Sandra Ammann, Tatjana I. Cornu, Fawad Khan, Tobias Wollmann, Sven Borchmann, Christof Scheid, Christianne de Lima Borges Moraes, Tobias Riët, Sabine Awerkiew, , Renata Stripecke

This study develops next-generation CD30CAR-T cells using CRISPR/Cas9 for multiplex editing, showing high potency but risks of translocations with combined knockouts.

bioRxiv · Feb 27, 2026 · PreprintCancer Biology

Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven immunomodulation

Daniel Bachurski, Rahil Gholamipoorfard, Yong Jia Bu, Patrick Hoelker, Lisa Wessendorf, Hendrik Jestrabek, Luca D Schreurs, David J. Stahl, Amin Mokhlesi, Philipp Gödel, Felix Gaedke, Elias Ranjbari, Selen Seyhan, Ulrike Resch, Luisa Marie Schmidt, , Nima Abedpour

The paper introduces TeLEV, a method to track EV proteomes in immune cells, revealing EV-driven immunomodulation through STAT5-dependent mechanisms.

bioRxiv · Nov 1, 2025 · PreprintCancer Biology

Topological Demarcation By HMGB2 Is Disrupted Early Upon Senescence Entry Across Cell Types And Induces CTCF Clustering

Anne Zirkel, Miloš Nikolić, Konstantinos Sofiadis, Jan‐Philipp Mallm, Lilija Brant, Christian Becker, Janine Altmüller, Julia Franzen, Mirjam Koker, Eduardo Gade Gusmao, Ivan G. Costa, Roland Tillmann Ullrich, Wolfgang Wagner, Peter Nürnberg, Karsten Rippe, Argyris Papantonis

The paper identifies HMGB2 loss as an early event in senescence that disrupts chromatin organization by inducing CTCF clustering across multiple human cell types.

bioRxiv · Apr 14, 2017 · PreprintGenomics